IMC
$12M23mo
Immuron
Gastrointestinal
Hyperimmune bovine colostrum antibodies for traveller's diarrhoea and NASH (Travelan, IMM-124E)
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$10.0M
Dec 2025 4C
Runway
23moSTABLE
Based on Dec 2025 4C
Market Cap
$12M
Burn Rate
$1.3M/qtr
Dec 2025 4C
Shares Outstanding
327M
Pipeline Assets
3
3M Price
IMC.ASX$0.037+27.6% 3M
Low $0.026High $0.047
Pipeline Assets (3)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
3 noticesarrow_drop_upThe Bank of New York Mellon Corporation (BNY) and each Group Entity listed in Annexure A
42.59%2026-06-02
arrow_drop_downThe Bank of New York Mellon Corporation and each Group Entity listed in Annexure A
Catalysts (6)· 0 upcoming · 6 past
expand_more6 past catalysts
Confirmedarrow_upwardHigh13 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT02316717
Confirmedarrow_upwardHigh13 Apr 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials